Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

Fate Therapeutics (NASDAQ:FATE – Free Report) had its target price trimmed by Wells Fargo & Company from $5.00 to $4.00 in a ...

As the U.S. stock market faces a turbulent period with major indices like the Dow Jones and S&P 500 on track for their worst week in two years, concerns about tariffs and economic health continue to ...

Maravai LifeSciences Holdings, Inc.’s MRVI share price has surged by 10.86%, which has investors questioning if this is right ...

StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF – Get Free Report) in a report issued on Friday. The brokerage set a “sell” rating on the stock. Several other brokerages have ...

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (the "Company"), a biopharmaceutical company dedicated to ...

Stevanato's 2024 revenue hits €1.1B, driven by biopharma growth! Discover how facility expansions & rising demand are transforming their market impact.

which are available on the SEC’s website at www.sec.gov. Contacts AEON Biopharma NewsMORE Related Stocks ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Xeris Biopharma climbed after the company guided for higher revenue in 2025. The stock was up 17%, to $4.41, in Thursday trading, which is equivalent to the highest close since June 28, 2021 ...